Quercefin, a bioflavonoid, reverses haloperidol-induced catalepsy

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 5, 2004, Pages 323-326

  Naidu, P S ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Catalepsy; Extrapyramidal side effects; Flavonoid; Haloperidol; Neuroleptics; Quercetin

Indexed keywords

BIOFLAVONOID; HALOPERIDOL; NEUROLEPTIC AGENT; QUERCETIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYKINESIA; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; HUMAN; MALE; MOOD DISORDER; MOUSE; NONHUMAN; PARKINSONISM; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; ANIMAL; CHEMICALLY INDUCED DISORDER;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MICE; QUERCETIN;

EID: 3242669796     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2004.26.5.831321     Document Type: Article

References (28)

1. Costall, B., Fortune, D.H., Naylor, R.J., Marsden, C.D., Pycock, C.J. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975, 14: 859-68.
2. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 1997, 131: 57-63.
3. Neal-beliveau, B.S., Joyce, J.N., Lucki, I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993, 265: 207-17.
4. Donaldson, McGregor D., Labella, F. Manganese neurotoxicity. A model for free radical mediated neurodegeneration. Can J Physiol Pharmacol 1982, 60: 390-405.
5. Longston, J.W., Ballard, P. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. New Eng J Med 1983, 309-10.
6. Burns, R.S., Chuang, C., Markey, S.P. et al. A primate model of Parkinsonism: Selective destruction of dopaminergic neurons in pars compacta of substantia nigra by N-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. Neurobiology 1983, 80: 4546-50.
7. 3H] MPTP may correspond to monoamine oxidase. Eur J Pharmacol 1984, 102: 375-7.
8. Miller, A.L. Antioxidant flavonoids: Structure, function and clinical usage. Alt Med Rev 1996, 1: 103-11.
9. Saija, A., Scalese, M., Lanza, M. Flavonoid as antioxidant agents: Importance of their interaction with biomembranes. Free Radic Biol Med 1992, 19: 481-6.
10. De Whalley, C.V., Rankin, J.F., Rankin, S.M. Flavonoids inhibit the oxidative modification of low density lipoproteins. Biochem Pharmacol 1990, 39: 1743-9.
11. Kaul, T.N., Middleton E. Jr, Ogra P.L. Antiviral effect of flavonoids on human viruses. J Med Virol 1985, 15: 71-9.
12. Bronner, C., Landry, Y. Kinetics of the inhibitory effect of flavonoids on histamine secretion from mast cells. Agents Actions 1985, 16: 147-51.
13. Cappaso, A., Piacente, S., Pizza, C., Sorrentino, L. Flavonoids reduce morphine withdrawal in-vitro. J Pharm Pharmacol 1998, 50: 561-4.
14. Morpogo, C. Effect of antiparkinson drugs on Phenothiazine induced catatonia reaction. Arch Int Pharmacodyn 1962, 137: 84-90.
15. Markey, S.P., Johannessen, J.N., Chiueh, C.C., Burns, R.S., Kerkenham, M.A. Interneuronal generation of pyridinium metabolite may cause drug-induced Parkinsonism. Nature 1984, 311: 464-9.
16. Cadet, J.L., Lohr, J.B., Jeste, D.V. Free radicals and tardive dyskinesia. Trends Neurosci 1986, 9: 107-8.
17. Cohen, G., Spina, M.B. Hydrogen production in neurones: Implications for understanding Parkinson's disease. In: Progress in Parkinson's Research. Hefti, E, Weiner, W.J. (Eds.). Plenum: New York 1988, 119-26.
18. Elkashef, A.M., Wyatt, R.J. Tardive dyskinesia: Possible involvement of free radical and treatment with vitamin E. Schrizophr Bull 1999, 25: 731-40.
19. Lee, M-H., Lin, R-D., Shen, L-Y., Yang, Y-Y., Yen, K-Y., Hou, W-C. Monoamino oxidase B and free radical scavenging activities of natural flavonoids in Melastoma candidum D. Don. J Argic Food Chem 2001, 49: 5551-5.
20. Fiorani, M., De Sanctis, R., Menghinello, P., Cucchiarini, L., Cellini, B., Dacha, M. Quercetin prevents glutathione depletion induced by dehydroascorbic acid in rabbit red blood cells. Free Rad Res 2001, 34: 639-48.
21. Melzig, M.F., Pertz, H.H., Krenn, L. Anti-inflammatory and spasmolytic activity of extracts from Droserae herba. Phytomedicine 2001, 8: 225-9.
22. Chen, Y.C., Shen, S.C., Lee, W.R., Hou, W.C, Yang, L.L., Lee, T.J. Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expression by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 2001, 82: 537-48.
23. Brus, R., Szkilnik, R., Slominsk-Zurek, J., Krzeminski, T., Herman, Z.S. Studies on the behavioral and hypotensive effects of intraventricular prostacyclin (PG 12) in rats. Pol J Pharmacol Pharm 1981, 33: 467-74.
24. Herman, Z.S., Slominsk-Zurek, J., Kryk, A., Kmieciak-Kolada, K. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins. Pol J Pharmacol Pharm. 1978, 30: 639-46.
25. Ferger, B., Teismann, P., Earl, C.D., Kuschinsky, K., Oertel, W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Nauyn Schmi Arch Pharmacol 1999, 360: 256-61.
26. Teismann, P., Ferger, B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Syanpse 2001, 39: 167-74.
27. Ono, N., Abiru, T., Sugiyama, K., Kamiya, H. Influence of cyclooxygenase inhibitors on the cataleptic behaviour induced by haloperidol in mice. Prost Leuk Esse Fat Acids 1992, 46: 59-63.
28. Naidu, P.S., Kulkarni, S.K. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiat 2002, 26: (In Press).